Allianz Asset Management
AKBA icon

Allianz Asset Management’s Akebia Therapeutics AKBA Stock Holding History

Allianz Asset Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-59,431
Closed -$376K – 2452
2019
Q4 		$376K Buy
+59,431
New +$282K ﹤0.01% 2507
2018
Q3 		– Sell
-123,928
Closed -$1.24M – 2599
2018
Q2 		$1.24M Sell
123,928
-690
-0.6% -$6.91K ﹤0.01% 2145
2018
Q1 		$1.19M Buy
+124,618
New +$1.74M ﹤0.01% 2138
2017
Q4 		– Sell
-47,440
Closed -$933K – 2634
2017
Q3 		$933K Buy
+47,440
New +$729K ﹤0.01% 2275

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Allianz Asset Management's AKBA Position: Q1 2020 in Review

Allianz Asset Management sold out of Akebia Therapeutics (AKBA) in Q1 2020, closing a stake of 59,431 shares — an estimated $376K sold.

Allianz Asset Management first reported a position in AKBA in Q3 2017 and held it in 4 quarters. The position peaked at $1.24M in Q2 2018. 155 funds tracked by Wall St. Rank hold AKBA as of Q1 2020.

  • Allianz Asset Management reported no remaining Akebia Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Allianz Asset Management sold 59,431 Akebia Therapeutics shares in Q1 2020, an estimated $376K.
  • Allianz Asset Management first reported a position in Akebia Therapeutics in Q3 2017 and held it in 4 quarters.
  • Allianz Asset Management's Akebia Therapeutics position peaked at $1.24M in Q2 2018.
  • 155 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2020.

Based on Allianz Asset Management's 13F filing for Q1 2020, filed 14 May 2020.